吡罗昔康的药代动力学:新进展。

H Fenner
{"title":"吡罗昔康的药代动力学:新进展。","authors":"H Fenner","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Some new aspects of the pharmacokinetics of piroxicam have recently become of interest because of the wide use of this compound. Recent studies have provided data on several questions: Are the disposition kinetics of piroxicam different from those of nonsteroidal anti-inflammatory drugs (NSAIDs) with a short half-life, and are the differences in transsynovial distribution relevant to anti-inflammatory activity and significant in the clinical use of these drugs in acute and chronic rheumatic conditions? Are there important differences in the disposition and elimination of piroxicam from patient to patient and in special subgroups such as elderly patients? Is the variation in the half-life of a drug within a given population significant, especially with regard to the rate of metabolic degradation, enterohepatic recirculation, and tubular reabsorption?</p>","PeriodicalId":12056,"journal":{"name":"European journal of rheumatology and inflammation","volume":"8 1","pages":"42-8"},"PeriodicalIF":0.0000,"publicationDate":"1987-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Pharmacokinetics of piroxicam: new aspects.\",\"authors\":\"H Fenner\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Some new aspects of the pharmacokinetics of piroxicam have recently become of interest because of the wide use of this compound. Recent studies have provided data on several questions: Are the disposition kinetics of piroxicam different from those of nonsteroidal anti-inflammatory drugs (NSAIDs) with a short half-life, and are the differences in transsynovial distribution relevant to anti-inflammatory activity and significant in the clinical use of these drugs in acute and chronic rheumatic conditions? Are there important differences in the disposition and elimination of piroxicam from patient to patient and in special subgroups such as elderly patients? Is the variation in the half-life of a drug within a given population significant, especially with regard to the rate of metabolic degradation, enterohepatic recirculation, and tubular reabsorption?</p>\",\"PeriodicalId\":12056,\"journal\":{\"name\":\"European journal of rheumatology and inflammation\",\"volume\":\"8 1\",\"pages\":\"42-8\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1987-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European journal of rheumatology and inflammation\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European journal of rheumatology and inflammation","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

由于吡罗西康的广泛应用,吡罗西康药代动力学的一些新方面最近引起了人们的兴趣。最近的研究提供了几个问题的数据:吡罗昔康的处置动力学与半衰期短的非甾体抗炎药(NSAIDs)的处置动力学是否不同,经滑膜分布的差异是否与抗炎活性有关,在急性和慢性风湿病的临床应用中是否重要?在不同患者和特殊亚群(如老年患者)之间,吡罗西康的处置和消除是否存在重要差异?药物在特定人群中的半衰期变化是否显著,特别是在代谢降解、肠肝再循环和小管重吸收方面?
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Pharmacokinetics of piroxicam: new aspects.

Some new aspects of the pharmacokinetics of piroxicam have recently become of interest because of the wide use of this compound. Recent studies have provided data on several questions: Are the disposition kinetics of piroxicam different from those of nonsteroidal anti-inflammatory drugs (NSAIDs) with a short half-life, and are the differences in transsynovial distribution relevant to anti-inflammatory activity and significant in the clinical use of these drugs in acute and chronic rheumatic conditions? Are there important differences in the disposition and elimination of piroxicam from patient to patient and in special subgroups such as elderly patients? Is the variation in the half-life of a drug within a given population significant, especially with regard to the rate of metabolic degradation, enterohepatic recirculation, and tubular reabsorption?

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信